HPLC Method for Analysis of Fitusiran on OligoMG Column
Separation type: Bridge Ion Separation Technology, or BIST™ by SIELC Technologies
Fitusiran is a relatively new therapeutic agent developed for the treatment of hemophilia A and B , including in patients with or without inhibitors.
Using SIELC’s newly introduced BIST™ method, this oligonucleotide can be retained on a OligoMg column. Using this new and unique analysis method, oligonucleotide can be separated, retained, and detected at 260 nm.
Please read more on oligonucleotides analysis by HPLC in our June 2024 newsletter .
Methodenparameter
| Column | OligoMg, 4.6 x 100 mm, 3 µm, 100 Å, dual ended |
|---|---|
| Mobile Phase | Gradient MeCN60-10%, 10 min |
| Buffer | none |
| Flow Rate | 1.0 mL/min |
| Detection | UV 260 nm |